= Emerging. More than 5 years before clinical availability. (24.37%, 2023)
= Expected to be clinically available in 1 to 4 years. (39.50%, 2023)
= Clinically available now. (36.13%, 2023)
= In discovery stage of development. (0.00%, 2023)
= In process of being translated to clinical use. (0.00%, 2023)
= Clinically available now. (0.00%, 2023)
MSACL 2023 : Urich

MSACL 2023 Abstract

Self-Classified Topic Area(s): Emerging Technologies > Tox / TDM / Endocrine > Various OTHER

Poster Presentation
Poster #38a
Attended on Wednesday at 11:00

The Development of a Virtual Liquid Chromatography Method Development Tool

Melinda Urich(1), Justin Steimling(1), Jamie York(1), Chris Nelson(1), Tim Yosca(1), John Garrett(2)
(1) Restek Corporation, Bellefonte, PA(2) Analytical Innovations, Inc, Dayton, OH

Melinda Urich (Presenter)
Restek Corporation

Presenter Bio: Melinda “Mel” Urich is an Applications Scientist within the LC Solutions Department, with a primary focus on the development of novel applications in the Cannabis, Psychedelics and Food markets. In her previous role, she led the synthesis of silica, bonding of stationary phases, and new process implementations and improvements as an LC Manufacturing Chemist.

Abstract

INTRODUCTION: The development and optimization of liquid chromatography (LC) separations can be time consuming and costly, often requiring a number of steps including literature research, column selection, method scouting, method development, and method optimization. In an effort to eliminate these steps, an instrument-free, software modeling tool that gives users the ability to select compounds from a database and instantly model a separation on different column phases was developed. Optimization of the model can be performed while maintaining critical pair separations by adjusting for instrument/system effects (e.g. dwell volume and extra column volume), mobile phase preferences, number of gradient steps, and more. The modeler delivers a fast, no-cost starting point. The initial database consists of a Drugs of Abuse (DoA) library containing approximately 250 compounds with plans to continually expand the utility.

OBJECTIVES: To develop a chromatogram modeling tool that allows users to develop and optimize their LC methods virtually, improving data quality and laboratory efficiency without time-consuming in-lab method development.

METHOD: To build the chromatogram modeler, a DoA library containing approximately 250 compounds was created.

Retention times were first collected using a fast/slow gradient, 30°C/60°C temperature points, and ACN/MeOH mobile phases on a single column dimension. Some additional data points outside of these runs were also collected for the development of a semi-empirical correction factor that was used to improve modeling accuracy.

To assess the accuracy of the modeler, experiments comparing compound retention time values between wet-lab and modeled data were conducted. After the initial DoA library was built, the modeler was evaluated over four increasingly more complex stages of verification. In the final, most complex stage, new compounds not previously part of the initial DoA library were added and then compared by testing two different column dimensions, two different columns lengths, two different mobile phases, two different stationary phases, three different gradients programs, and three different temperatures against modeled retention time values. Because the semi-empirical correction factor was developed using only the original library compounds, this stage assessed the viability of adding future compounds to existing libraries.

RESULTS: An online chromatogram modeling tool was successfully developed that allows users to select columns and compounds for separation. A modeled chromatogram and instrument-ready conditions are automatically generated and can be further optimized by users. During software development, the acceptance criteria for retention time agreement between wet-lab and modeled values was set at +/- 15 seconds. This range was chosen because it represents a typical MRM window. In the most complex portion of the verification, 704 retention time data points were collected in total for the 25 compounds used in the evaluation. Only 13 data points exceeded the +/- 15 second window with no compounds missing acceptance criteria by more than five seconds, giving an overall pass rate of 98.2%.

CONCLUSION: For LC method developers, novice and expert, who either lack the expertise, or the time, to develop separations quickly and accurately, this free tool can be used to deliver a fast, no-cost starting point for method development and optimization. This novel, virtual method development software can improve turnaround time, increase throughput to existing methods, and offer an on-demand consultative user experience.


Financial Disclosure

DescriptionY/NSource
Grantsno
SalaryyesRestek Corporation
Board Memberno
Stockyes Restek Corporation
ExpensesyesRestek Corporation
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

yes